“Synthetic Embryos”: The Wrong Term For Important New Research

“Synthetic Embryos”: The Wrong Term For Important New Research

This fluorescent image shows a representative post-implantation amniotic sac embroid.

(Courtesy of Yue Shao)


Keep Reading Keep Reading
Norbert Gleicher
Dr. Norbert Gleicher founded the Center for Human Reproduction (CHR) in 1981, after completing his residency at the Mount Sinai School of Medicine in New York and holding top academic and administrative positions in various academic institutions in New York and Chicago. Always keen on simultaneously pursuing clinical care and research, Dr. Gleicher has published hundreds of peer-reviewed medical journal articles, abstracts and book chapters, in addition to editing textbooks that are now regarded as classics. Dr. Gleicher also holds adjunct professorship appointments at Rockefeller University in New York City, as well as Medical University Vienna.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.